Effects of ACE inhibition on cyclosporine A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats on a high-sodium diet

Blood Pressure

Volumn 8, Issue 1, 1999, Pages 49-56

  Mervaala, Eero ^a,c   Lassila, Markus ^a   Vaskonen, Timo ^a   Krogerus, Leena ^b   Lähteenmäki, Tuula ^a   Vapaatalo, Heikki ^a   Karppanen, Heikki ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

ACE; Angiotensin; Cyclosporine A; Enalapri; Proteinuria; Sodium

Indexed keywords

CALCIUM; CREATININE; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; MAGNESIUM; PROTEIN; RENIN;

AGED; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CALCIUM EXCRETION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; ENZYME INHIBITION; HYPERTENSION; KIDNEY FUNCTION; MAGNESIUM URINE LEVEL; MALE; NEPHROTOXICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROTEINURIA; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SALT INTAKE; SYSTOLIC BLOOD PRESSURE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BLOOD PRESSURE; BODY WEIGHT; CREATININE; CYCLOSPORINE; ENALAPRIL; HEART RATE; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY; POTASSIUM; RATS; RATS, INBRED SHR; RENIN-ANGIOTENSIN SYSTEM; SODIUM, DIETARY;

EID: 0033045032     PISSN: 08037051     EISSN: None     Source Type: Journal    
DOI: 10.1080/080370599438392     Document Type: Article

References (31)

1. Faulds D, Goa KL, Benfield P. Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs 1993; 45: 953-1040.
2. Textor SC, Canzanello VJ, Taler SJ, et al. Cyclosporine-induced hypertension after transplantation. Mayo Clin Proc 1994; 69: 1182-93.
3. Curtis JJ, Luke RG, Jones P, Diethelm AG. Hypertension in cyclosporine-treated renal transplant recipients is sodium dependent. Am J Med 1988; 85: 134-8.
4. Mervaala EMA, Pere A-K, Lindgren L, et al. Effects of dietary sodium and magnesium on cyclosporine A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats. Hypertension 1997; 29: 822-7.
5. Pere A-K, Krogerus L, Mervaala EMA, et al. Beneficial effect of dietary magnesium on glomerular changes in cyclosporin-A treated spontaneously hypertensive rats. Nephrol Dial Transplant 1998; 13: 904-10.
6. Burdmann EA, Andoh TF, Nast CC, et al. Prevention of experimental cyclosporin-induced interstitial fibrosis by losartan and enalapril. Am J Physiol 1995; 269: F491-9.
7. Pichler RH, Franceschini N, Young BA, et al. Pathogenesis of cyclosporine nephropathy: roles of angiotensin II and osteopontin. J Am Soc Nephrol 1995; 6: 1186-96.
8. Shihab FS, Bennett WM, Tanner AM, Andoh TF. Angiotensin II blockade decreases TGF-β1 and matrix proteins in cyclosporine nephropathy. Kidney Int 1997; 52: 660-73.
9. Laragh J, Baer L, Brunner H, Buhler F, Sealey J, Vaughan E. Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease. Am J Med 1972; 52: 633-52.
10. Waeber B, Nussberger J, Brunner HR. Angiotensin-converting-enzyme inhibitors in hypertension. In: Brenner BM, Laragh JH, editors. Hypertension: pathophysiology, diagnosis, and management. New York: Raven Press, 1990: 2209-32.
11. Mervaala EMA, Paakkari I, Laakso J, et al. Replacement of salt by a novel potassium-and magnesium-enriched salt alternative improves the cardiovascular effects of ramipril. Br J Pharmacol 1994; 111: 1189-97.
12. Mervaala EMA, Laakso J, Himberg J-J, Karppanen H. Replacement of regular salt by a novel salt alternative improves the cardiovascular effects of the ACE inhibitor enalapril. Hypertens Res 1994; 17: 59-69.
13. Linz W, Wiemer G, Gohlke P, Unger T, Schölkens B. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 1995; 47: 25-49.
14. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193: 265-75.
15. MacGregor GA, Markandu ND, Singer DR, Cappuccio FP, Shore AC. Moderate sodium restriction with angiotensin converting enzyme inhibitor in essential hypertension: a double blind study. Br Med J 1987; 294: 531-4.
16. Heeg J, de Jong P, van der Hem K, de Zeeuw D. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int 1989; 36: 272-9.
17. Millane TA, Wilson AJ, Patel MK, et al. Mitochondrial calcium deposition in association with cyclosporine therapy and myocardial magnesium depletion: a serial histologic study in heart transplant recipients. J Heart Lung Transplant 1994; 13: 473-80.
18. Molkentin JD, Lu J-R, Antos CL, et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998; 93: 215-28.
19. Kreutz R, Fernandez-Alfonso MS, Liu Y, Ganten D, Paul M. Induction of cardiac angiotensin I-converting enzyme with dietary NaCl-loading in genetically hypertensive and normotensive rats. J Mol Med 1995; 73: 243-8.
20. Hall JE. Regulation of of glomerular filtration rate and sodium excretion by angiotensin II. Fed Proc 1986; 45: 1431-7.
21. Franco M, Paniagua R, Herrea-Acosta J. Renal effects of renin-angiotensin system blockade. Curr Opin Nephrol Hypertens 1998; 7: 153-8.
22. Harris PJ, Navar LG. Tubular transport responses to angiotensin. Am J Physiol 1985; 248: F621-30.
23. Van Der Mark J, Kline RL. Altered pressure natriuresis in chronic angiotensin II hypertension in rats. Am J Physiol 1994; 266: R739-48.
24. Johnson RJ, Alpers CE, Yoshimura A, et al. Renal injury from angiotensin II-mediated hypertension. Hypertension 1992; 19: 464-74.
25. 2+. Circ Res 1994; 74: 477-84.
26. Diederich D, Skopec J, Diederich A, Dai F-X. Cyclosporine produces endothelial dysfunction by increased production of superoxide. Hypertension 1994; 23: 957-61.
27. Marumo T, Nakaki T, Hishikawa K, Suzuki H, Kato R, Saruta T. Cyclosporin A inhibits nitric oxide synthase induction in vascular smooth muscle cells. Hypertension 1995; 25: 764-8.
28. Bobadilla NA, Tapia E, Franco M, et al. Role of nitric oxide in renal hemodynamic abnormalities of cyclosporin nephrotoxicity. Kidney Int 1994; 46: 773-9.
29. Bech Laursen JB, Rajagopalan S, Galis Z, Tarpey M, Freeman BA, Harrison DG. Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation 1997; 95: 588-93.
30. Oskarsson HJ, Heistad DD. Oxidative stress produced by angiotensin too: implications for hypertension and vascular injury. Circulation 1997; 95: 557-9.
31. Laakso J, Mervaala E, Himberg J-J, et al. Increased kidney xanthine oxidoreductase activity in salt-induced experimental hypertension. Hypertension 1998; 32: 902-6.